No Survival Advantage of Intermediate Radiotherapy Dose Escalation in Stage III NSCLC Receiving Delayed Immunotherapy after Chemoradiation
Asian Journal of Current Research in Clinical Cancer · 2026 · 6 (1) · 59-75
DOI: 10.51847/1d1hozjkgn ↗Kurz gefasst
Fachartikel in der Zeitschrift Asian Journal of Current Research in Clinical Cancer, 2026. Verfasst von Jinwoo Park und 2 weiteren Autor:innen. Die Arbeit nennt 40 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Park, J., Kim, M., & Lee, S. (2026). No Survival Advantage of Intermediate Radiotherapy Dose Escalation in Stage III NSCLC Receiving Delayed Immunotherapy after Chemoradiation. Asian Journal of Current Research in Clinical Cancer, 6(1), 59-75. https://doi.org/10.51847/1d1hozjkgn
Vancouver
Park J, Kim M, Lee S. No Survival Advantage of Intermediate Radiotherapy Dose Escalation in Stage III NSCLC Receiving Delayed Immunotherapy after Chemoradiation. Asian Journal of Current Research in Clinical Cancer. 2026;6(1):59-75. doi:10.51847/1d1hozjkgn
BibTeX
@article{Park2026,
author = {Park, Jinwoo and Kim, Minji and Lee, Seung},
title = {No Survival Advantage of Intermediate Radiotherapy Dose Escalation in Stage III NSCLC Receiving Delayed Immunotherapy after Chemoradiation},
journal = {Asian Journal of Current Research in Clinical Cancer},
year = {2026},
volume = {6},
number = {1},
pages = {59--75},
doi = {10.51847/1d1hozjkgn}
}
EUVIMED